Spatial information is significantly decreased in dCA1 and vCA1 in APP/PS1 mice. by Udaysankar Chockanathan (18510288)

“…(B) In dCA1, spatial information was decreased in APP/PS1 mice relative to C57BL/6 controls (mean ± std: C57BL/6 = 0.132 ± 0.048, APP/PS1 = 0.128 ± 0.051, p < 0.005, two-sided Wilcoxon rank-sum test, n_C57BL/6 = 305 units from 5 recording sessions, n_APP/PS1 = 180 units from 4 recording sessions). …”

Task variability/correlations decrease independently of mean task activity removal step in fMRI data. by Takuya Ito (57473)

HRV parameters at different time points. by Shiying Liu (1569478)

Subjects:

Pearson’s correlation showing significant correlations (<i>P</i> < 0.05) between microbiota and clinical variables in the Staph group. by Paulo Kussek (13410476)

PAP I point mutations lead to a decrease in pYV PCN, plasmid stability, and T3SS activity. by Katherine Schubert (5452712)

PSG-specific <i>Fzr</i> mutation decreases the expression of silk protein genes. by Wenliang Qian (639395)

“…Values were represented as means ±S.E. (error bars). For the significance test: *<i>P</i> < 0.05, **<i>P</i> < 0.01, and ***<i>P</i> < 0.001 versus the control. …”

Homozygous deletion of the orthologous murine <i>Ikzf1</i> enhancer results in significantly decreased <i>Ikzf1</i> expression, increased cell proliferation, and altered B cell dif... by Vincent U. Gant (9955199)

The BMP pathway decreases the ability of colonocytes to grow without anchoring. by Jacques Dupuy (6670244)

HA-MAD1 tumors have increased CIN and decreased p53. by Sarah E. Copeland (13951506)

SARS-CoV-2 induced lung inflammation is increased with IL-10 blockade and decreased with IFNγ blockade. by Christine E. Nelson (18946410)

Divergence from transmitted/founder (TF) virus increases during ART-naïve infection and decreases on treatment. by Kelsie Brooks (8928044)

DNMT inhibitor decreases expression of inhibitor receptors on the repeat peptide stimulated cells. by Manzhi Zhao (9023381)

Repeat peptide stimulation decreases <i>in vivo</i> CTL expansion capacity. by Manzhi Zhao (9023381)

Summary of post-treatment disease course measures from MDMA-AT publications. by Filip Stanicic (17808254)

Subjects:

Study selection criteria. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications. by Filip Stanicic (17808254)

Subjects:

Disease course measures after the PTSD treatments. by Filip Stanicic (17808254)

Subjects:

PICOS criteria for the SLR. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment CAPS score changes from MDMA-AT publications. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment disease course measures from off-label medications clinical trials. by Filip Stanicic (17808254)

Subjects: